



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

CGS 15943

Cat. No.:	HY-100678
CAS No.:	104615-18-1
Molecular Formula:	C ₁₃ H ₈ ClN ₅ O
Molecular Weight:	285.69
Target:	Adenosine Receptor; PI3K
Pathway:	GPCR/G Protein; PI3K/Akt/mTOR
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 12.22 mg/mL (42.77 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		3.5003 mL	17.5015 mL	35.0030 mL
		5 mM		0.7001 mL	3.5003 mL	7.0006 mL
		10 mM		0.3500 mL	1.7501 mL	3.5003 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 1.22 mg/mL (4.27 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 1.22 mg/mL (4.27 mM); Suspended solution; Need ultrasonic					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil					
	Solubility: ≥ 1.22 mg/mL (4.27 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	CGS 15943 is an orally bioavailable non-xanthine Adenosine Receptor antagonist. Its K _i for human A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2, 16, and 50 nM in transfected CHO cells, respectively. ^{[1][2]}			
IC ₅₀ & Target	p110γ 1.1 μM (IC ₅₀)	p110δ 8.47 μM (IC ₅₀)	adenosine A1 receptor 3.5 nM (K _i)	adenosine A2A receptor 4.2 nM (K _i)
	adenosine A2B receptor 16 nM (K _i)	adenosine A3 receptor 50 nM (K _i)		

In Vitro

CGS 15943 inhibits the kinase activity of the class IB PI3K isoform p110 γ with an IC₅₀ of 1.1 μ M and shows slight inhibition on p110 δ with an IC₅₀ of 8.47 μ M^[3].

CGS 15943 (0-20 μ M; 72 hours) inhibits growth of HLF and SK-Hep-1 cells, as well as HepG2 and PLC-PRF-5 cells^[3].

CGS 15943 (0-20 μ M; 24 hours) reduces the phosphorylation of Akt at its residues Ser473 and Thr308 in HLF and Sk-Hep-1 cells^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:	HLF, SK-Hep-1, HepG2 and PLC-PRF-5 cells
Concentration:	0 μ M; 1 μ M; 5 μ M; 10 μ M; 20 μ M
Incubation Time:	24 hours
Result:	Inhibited growth of four distinct HCC cell lines.

Western Blot Analysis^[3]

Cell Line:	HLF and Sk-Hep-1 cells
Concentration:	0 μ M; 1 μ M; 5 μ M; 10 μ M; 20 μ M
Incubation Time:	24 hours
Result:	Inhibited the PI3K/Akt pathway in HLF and Sk-Hep-1 cells

REFERENCES

[1]. Gao Y, et al. CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci. 1994;55(3):PL61-5.

[2]. Klotz KN, et al. Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):382-91.

[3]. Edling CE, et al. Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol Ther. 2014 May;15(5):524-32.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA